Document Detail


Effect of angiotensin II type-1 receptor blockers on stable allograft kidneys: prospective randomized study.
MedLine Citation:
PMID:  19765449     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Is assess the effects of angiotensin II type-I receptor blockers on outcomes in renal transplant recipients without proteinuria or posttransplantation erythrocytosis. PATIENTS AND METHODS: Fifty renal transplant recipients (30 men and 20 women, with a mean [SD] age of 40 [13] years) were randomized into 2 groups of 25 patients each; 1 group was treated with losartan for 1 year, and the other was not (control group). Blood pressure and other biochemical parameters were measured at baseline and at 6 and 12 months posttransplantation. RESULTS: After 1 year, the losartan group had significantly lower systolic blood pressure (113 [22] mm Hg vs 126 [18] mm Hg; P = .04) and hemoglobin concentration (12.8 [1.9] g/dL vs 14.5 [2.1] g/dL; P = .006) and significantly higher serum high-density lipoprotein cholesterol concentration (58 [22] mg/dL vs 47 [10] mg/dL; P = .03) compared with the control group; however the incidence of anemia did not differ (37% vs 20%; P = .20). In the losartan group, there were significant changes in hemoglobin concentration between baseline and 6 months (14.5 [1.6] g/dL vs 12.9 [1.49] g/dL; P < .001), but not between 6 and 12 months (12.9 [1.49] g/dL vs 12.8 [1.96] g/dL; P = .43). After 1 year, there were no significant between-group differences in diastolic hypertension, serum creatinine concentration, creatinine clearance, and serum potassium, low-density lipoprotein cholesterol, triglyceride, and uric acid concentrations. CONCLUSION: Losartan significantly increased high-density lipoprotein concentration and significantly decreased systolic hypertension. Although losartan decreased the hemoglobin concentration during the first 6 months, its effect did not progress with longer use. To determine the effect of losartan on renal function, additional studies with longer follow-up are needed.
Authors:
N Nouri-Majalan; A Ghafari; S Moghaddasi
Related Documents :
24841919 - Functional and practical outcomes of inlay butterfly cartilage tympanoplasty.
11050699 - Pharmacodynamic study of low molecular weight dermatan sulphate (desmin) after a single...
2189149 - The medical research council trial of short-term high-dose alternate day prednisolone i...
24669119 - Clinical predictors of nocturia in the sleep apnea population.
23949459 - The neuroprotective role of therapeutic hypothermia after cardiac arrest.
22927149 - Biphasic calcium phosphate contained within a polyetheretherketone cage with and withou...
16133889 - Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-te...
23579339 - Tumor origin and growth pattern at diagnosis and surgical hypothalamic damage predict o...
24429379 - Impact of patient access to internet health records on glaucoma medication: randomized ...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Transplantation proceedings     Volume:  41     ISSN:  1873-2623     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-21     Completed Date:  2010-01-11     Revised Date:  2010-03-03    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2832-4     Citation Subset:  IM    
Affiliation:
Nephrology Department, Sadoughi Medical University, Azad University, Yazd, Iran. dr_nori_majelan@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Cholesterol, HDL / blood
Creatinine / blood
Female
Humans
Kidney Transplantation / physiology*
Losartan / therapeutic use*
Male
Middle Aged
Polycythemia / blood,  drug therapy,  epidemiology
Postoperative Complications / blood,  drug therapy,  epidemiology
Potassium / blood
Prospective Studies
Systole / drug effects
Transplantation, Homologous
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Cholesterol, HDL; 114798-26-4/Losartan; 60-27-5/Creatinine; 7440-09-7/Potassium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of renal transplantation on coronary artery calcification in hemodialysis patients.
Next Document:  Relationship of renal resistive index and cardiovascular disease in renal transplant recipients.